Medivir

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Our mission is to developproprietary and differentiated pharmaceuticals that alleviate suffering and improve the lives of patients in selected therapeutic areas.

Our vision is to become a leading, innovative and competitive research and development-based biopharmaceutical company and become a leader in oncology, virology and inflammation through the development and commercialization of innovative medicines and treatments

Medivir has been recognized for its innovative and entrepreneurial approach. Over the past few years alone, it has won the Stockholm Innovation Award, and its antiviral drug Emtricitabine won a Swedish Wallmark Prize in 2017. Its HLA-G project was also crowned 'Project of the Year' at the Nordic Life Science Days in 2016.